Tivicay, a combo HIV drug from GlaxoSmithKline, Pfizer and Shionogi that is pegged to become a blockbuster, was only approved last summer, but the companies are having to recall a small portion of it because of cross-contamination.
Cutting supply chain costs has become a focus of the industry as drugmakers realized that buying supplies and getting them to plants takes more time, trouble and expense than they at first realized. Like others, U.K. drugmaker GlaxoSmithKline has taken steps to get a handle on that, LogisticsManager reports.
The Lieber Institute for Brain Development is partnering with Astellas, Eli Lilly, Lundbeck, Pfizer and Roche to launch an early-stage research consortium to study the genetic mechanisms at work in brain disorders.
In the first detailed glimpse of palbociclib's impact on overall survival--a key feature to the future prospects of this flagship program--the therapy has failed to demonstrate a statistically significant improvement in extending patients' lives after an initial assessment.
Analysts will be all ears as the company sheds light on its would-be blockbuster.
Last month Pfizer and the Broad Institute published details of their work to find diabetes drug targets in genome data. Now Pfizer has teamed with Merck KGaA to give the institute another pot of cash to investigate lupus.
Pfizer's venture investment arm is the lead backer in NeuMoDx Molecular's new $21 million Series B round. The Michigan startup attracted a new batch of financing designed to propel development of a highly efficient, low-cost molecular diagnostics platform and tests that can be run on it.
Rival drugmakers Merck KGaA and Pfizer are putting their cash and expertise into a new effort to better understand lupus, tapping the Broad Institute for a Big Data approach to help map out the disease and light the way for future drug candidates.
AstraZeneca has been pulling out all the stops in trying to preserve blockbuster Nexium's revenues for as long as it can. Now, the FDA has approved an over-the-counter version of the drug--but thanks to a 2012 agreement, those sales are on their way to Pfizer.
Thanks to genomic sequencing, some heart-healthy mutants and billions of dollars spent on R&D, rival drug developers are bearing down on a promising new way of treating the scourge of high cholesterol. And with the first FDA applications likely coming in the next year, the nascent field's trailblazers are vying for the top spot with blockbuster aspirations.